Newsfeeds Archive - Spark Newswire

1 minute read

Precipio And Cardinal Health Sign Distribution Agreement For Its HemeScreen Portfolio Of Molecular Assays For Cancer

February 6, 11:00 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement,

CAH

2 minute read

News

Precipio’s Q4-2023 Cash Burn From Operations Drops Below $100K For The Full Quarter; Precipio’s End Of Quarter Cash Balance Changed From ~$1.5M At The End Of Q3-2024, To ~$1.4M As Of Dec 31, 2023

By Benzinga Newsdesk

January 23, 11:06 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that continued revenue growth generated cash levels that bring the company closer to breakeven. Cash Burn From Operations (CBFO) declined by

PRPO

2 minute read

Precipio Signs Distribution Agreement For IV-Cell And HemeScreen In Japan

By Benzinga Newsdesk

January 17, 11:30 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The

PRPO

1 minute read

Precipio Sees Q3 Revenue $4.5M Vs $4M Est.

By Benzinga Newsdesk

October 18, 9:06 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.The

PRPO

2 minute read

Precipio Continues To Sign New HemeScreen Customers Expected To Bring Total Q4 HemeScreen Revenues To An Estimated $1.2M

By Benzinga Newsdesk

September 28, 9:06 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M.In a recent announcement, the

PRPO

2 minute read

Precipio Reduces Product Revenue Result Needed For Cash Flow Breakeven From $8M To $6M Annually, Or $1.5M Per Quarter, 25% Below Previous Estimates

By Benzinga Newsdesk

September 25, 11:01 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required

PRPO